Long-Term Follow-up Confirms Low Incidence of Cardiac Events Associated With Trastuzumab


Get Permission

At a median follow-up of 8 years, patients receiving trastuzumab (Herceptin) sequentially after chemotherapy and radiotherapy in the Herceptin Adjuvant (HERA) trial had a low incidence of cardiac events and these were reversible in the vast majority of patients. This long-term assessment confirms and extends previous reports of cardiac safety.

The three-arm HERA trial compared 2 years or 1 year of trastuzumab with observation in 5,102 patients with human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer. “This is the first time that results of the 2-year trastuzumab arm have been reported, and the follow-up time has doubled,” researchers reported in the Journal of Clinical Oncology.

Eligible patients had a left-ventricular ejection fraction of at least 55% following neoadjuvant chemotherapy with or without radiotherapy and cardiac function was closely monitored. Cardiac adverse events leading to discontinuation of trastuzumab occurred in 9.4% of the 1,673 patients receiving 2 years of trastuzumab and 5.2% of the 1,682 patients receiving 1 year of trastuzumab.

Cardiac death, severe congestive heart failure, and confirmed significant left-ventricular ejection fraction decrease remained low in both treatment and the observation arms. “The incidence of severe [congestive heart failure] (0.8%, 0.8%, and 0.0%, respectively) and confirmed significant [left-ventricular ejection fraction] decrease (7.2%, 4.1%, and 0.9%, respectively) was significantly higher in the 2-year and 1-year trastuzumab arms compared with the observation arm. Severe [congestive heart failure] was the same for 2-year and 1-year trastuzumab,” the investigators stated. More than 80% of patients with confirmed left-ventricular ejection fraction decrease receiving trastuzumab for 1 or 2 years reached acute recovery, defined as two or more sequential left-ventricular ejection fraction assessments of > 50%.

“Importantly, our data are consistent with the reassuring cardiac safety data reported in the other pivotal adjuvant trastuzumab trials testing the 1-year trastuzumab duration,” the authors noted. This includes the NSABP B-31 trial, which reported a 4.0% incidence of cardiac events in the trastuzumab arm vs 1.3% in the control arm, with most of those experiencing a cardiac event recovering within 6 months.

“Despite this low incidence of cardiac toxicity in our trial, patients treated with adjuvant trastuzumab should have a cardiac assessment before and during its administration to ensure the early detection of cardiac events and prompt treatment,” the authors advised. ■

de Azambuja E, at al: J Clin Oncol. June 9, 2014 (early release online).


Advertisement

Advertisement



;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.